Victoria López-Codony, Álvaro de Andrés-Pablo, Angelica Ferrando-Díez, Maria Eulàlia Fernández-Montolí, Marta López-Querol, Sara Tous, Carlos Ortega-Expósito, Juan Carlos Torrejón-Becerra, Yolanda Pérez, Anna Ferrer-Artola, Josep Maria Sole-Sedeno, Clara Grau, Blas Rupérez, Maria Saumoy, Mónica Sánchez, Paula Peremiquel-Trillas, Laia Bruni, Laia Alemany, Francesc Xavier Bosch, Miquel Angel Pavón
Human Papillomavirus (HPV) prophylactic vaccination has proven effective in preventing new infections, but it does not treat existing HPV infections or associated diseases. Hence, there is still an important reservoir of HPV in adults, as vaccination programs are mainly focused on young women. The primary objective of this non-randomized, open-label trial is to evaluate if a 3-dose regimen of Gardasil-9 in HPV16/18-positive women could reduce the infective capacity of their body fluids. We aim to assess if vaccine-induced antibodies could neutralize virions present in the mucosa, thus preventing the release of infective particles and HPV transmission to sexual partners...
2024: PloS One